The COVID Clinical Trials team seeks adults with chronic kidney disease on or off dialysis for a research study. The purpose of the study is to test the safety or an oral medication to treat COVID-19.
If you develop symptoms of COVID-19, please consider joining a COVID-19 oral treatment study of PF-07321332 (nirmatrelvir/ritonavir; brand name PAXLOVIDTM). Adults who have chronic kidney disease (renal impairment) receiving or not receiving hemodialysis treatment with mild to moderate COVID-19, may be able to participate. All participants will receive the study medicine, PAXLOVID.
Study involves taking medication twice daily for 5 days, daily labs (some at home and some in clinic or by home health), and daily log entries through an app on your phone.
Contact the study team as soon as possible after you develop symptoms of COVID-19. Participants must have developed signs and symptoms within 5 days before joining the study.
Study-related testing, medication, and software are provided at no cost.
You will be compensated up to $225 per visit.